AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival ("DFS") expected in H1 2025Poster presentation at the Society for Im ...
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...
Presentation of Strong Preclinical Dataset: On September 25, 2024, HOOKIPA presented the preclinical proof-of-concept dataset ...
The Santa Clarita Valley Water Public Outreach and Legislation Committee will hold a meeting Thursday, Nov. 21, at 5:30 p.m., ...
Consolidated revenue of €3.4m at the end of September 2024 Cash position of €4.1m before receipt of IRIS Pharma's CIR (€610k) as of September 30, 2024 Live broadcast of the General Meeting ...
Poster Hall C Presented by Professor Henkjan Verkade, University of Groningen, Groningen, Netherlands Alagille Syndrome Patient & Physician Fireside Discussion During the meeting, Mirum will host a ...
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company ...
Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback